Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

about

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

Item

http://www.wikidata.org/entity/Q58560605

description

im November 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 09 November 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в листопаді 2018

@uk

name

Interpreting clinical trial da ...... ings to the real-world setting

@en

Interpreting clinical trial da ...... ings to the real-world setting

@nl

type

Item

label

Interpreting clinical trial da ...... ings to the real-world setting

@en

Interpreting clinical trial da ...... ings to the real-world setting

@nl

prefLabel

Interpreting clinical trial da ...... ings to the real-world setting

@en

Interpreting clinical trial da ...... ings to the real-world setting

@nl

P1476

Interpreting clinical trial da ...... ings to the real-world setting

@en

P2093

Dorothy Romanus

http://www.w3.org/2001/XMLSchema#string

Jacob P Laubach

http://www.w3.org/2001/XMLSchema#string

Katarina Luptakova

http://www.w3.org/2001/XMLSchema#string

Meletios A Dimopoulos

http://www.w3.org/2001/XMLSchema#string

Tomas Skacel

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

Adaptive Designs for Clinical Trials

Non-secretory myeloma: a clinician's guide

Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

P2888

s41408-018-0141-0

P304

109

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41408-018-0141-0

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P5008

ScienceSource

P577

2018-11-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30413684

http://www.w3.org/2001/XMLSchema#string

P921

hematology

multiple myeloma

biomedical investigative technique

P932

6226527

http://www.w3.org/2001/XMLSchema#string